Bennett Lawrence Management’s Neurocrine Biosciences NBIX Stock Holding History

Bennett Lawrence Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$804K	Buy	+14,215	New	+$722K	0.26%	76

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bennett Lawrence Management's NBIX Position: Q4 2015 in Review

Bennett Lawrence Management opened a new position in Neurocrine Biosciences (NBIX) in Q4 2015: 14,215 shares worth $804K. The stake represents 0.26% of the portfolio and ranks #76 among its holdings.

219 funds tracked by Wall St. Rank hold NBIX as of Q4 2015.

Bennett Lawrence Management held 14,215 shares of Neurocrine Biosciences worth $804K as of Q4 2015.
Neurocrine Biosciences was a new Bennett Lawrence Management position in Q4 2015.
Neurocrine Biosciences made up 0.26% of Bennett Lawrence Management's portfolio in Q4 2015, its #76 holding.
219 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2015.

Based on Bennett Lawrence Management's 13F filing for Q4 2015, filed 16 Feb 2016.